Analystreport

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its "buy" rating re-affirmed by analysts at SVB Leerink LLC. They now have a $10.00 price target on the stock.

CymaBay Therapeutics Inc.  (CBAY) 
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cymabay.com